WB007
Phase 2- Indications
- Glaucoma
Company intelligence / Profile preview
Whitecap Biosciences
Unknown, California, United Statesir.bausch.com ↗
- Ownership
- Public · BLCO
- Development stage
- Phase 2
01
Overview
Whitecap Biosciences successfully completed Phase 2 clinical trials for WB007, a highly potent alpha-2 adrenergic agonist, in glaucoma. The trial evaluated the safety and IOP-lowering effects of WB007 in adults with primary open-angle glaucoma or ocular hypertension in both eyes. Results showed a reduction in IOP from baseline at day 14.[1][2]
- Therapeutic areas
- Ophthalmology
- Modalities
- Alpha-2 adrenergic agonist (WB007)
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Whitecap Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Whitecap Biosciences.